Microsoft word - consent_mps
Dr Geoff Bower
Patient History for HEART SCANS (Myocardial Perfusion Studies)
Patient Name: ___________________________________ Date of birth: _____________________
Telephone Home: ______________ Mobile: _____________________ Work: _________________
Name of contact person in case of emergency: ________________ Telephone: ________________
For female patients only - is there any chance you may be pregnant?
- are you breastfeeding? Yes / No
- are you taking an oral contraceptive pill
Prior Heart Scan? Yes / No
If yes, when and where: _________________________________
Why has your doctor referred you for a heart scan? (e.g. chest pain, recent heart attack, etc) _____
Have you ever had a heart attack?
If yes, when: __________________________
Have you ever smoked? Yes / No
If yes, when did you stop smoking? __________________
Do you experience chest pain or discomfort? Yes / No
Do you experience breathlessness?
Do you have a family history of heart problems?
_______________________________________________________________________________ Do you have diabetes?
If yes, how is it controlled? (e.g. pills, injections) _________
Do you have any problems walking or cycling? Yes / No
If yes, please describe (e.g. calf pain,
angina, shortness of breath, arthritis, etc) ___________________________________________
Please list ANY
previous surgeries: ___________________________________________________
Please list ANY
past medical conditions: _______________________________________________
Please list ALL
current medications: __________________________________________________
Please list ANY
allergies: (e.g. sulphur, nitrates, drugs, etc) ________________________________
_______________________________________________________________________________ For male patients only
: Are you currently being treated with Viagra?
STRESS HEART SCAN
Exercise testing measures the ability of the heart and lungs to function under a gradually increasing load. In most cases, the test is carried out for diagnosis or assessment of the severity of coronary artery disease. An intravenous injection line is inserted in an arm vein before testing commences. A resting electrocardiogram is recorded prior to exercise. The test is performed on a treadmill or an exercise bike. A drug called dipyridamole may be used to simulate the effects of maximum exercise. This may have some effects such as flushing, chest pain and headache, but these are usually short-lived and minimized by walking on the treadmill (during injection over four minutes). The effects of dipyridamole are reversed with another drug, a few minutes after the isotope is given.
Clinical exercise stress testing is usually performed in patients with known or suspected coronary
artery disease. While every effort is made to minimize the risk of the procedure, there is a very small
but definite risk of complications.
Possible complications include heart attack. The risk of this occurring is approximately 2 per 10,000
tests, or once in 15 years if you were to have this test every day. Unfortunately, there is also a very
small risk of death occurring as a result of the exercise test. The chance of this in the average
patients is less than 1 in 10,000. This needs to be weighed against the risk of not having the test, as
undiagnosed coronary artery disease may pose a much greater risk. In people with a recent stoker
(or other brain/ nervous problem) the test may need to be delayed. Speak to your specialist about
Throughout the test a doctor is present, and the patient’s pulse, blood pressure and
electrocardiogram (ECG) are monitored. Emergency equipment and trained personnel are available
to deal with any complications that may arise. I have read this form, understand the purpose and the risks of the tests, and consent to the
test being performed.
Peter Satterthwaite Senior Portfolio Manager Capital & Coast District Health Board Private Bag 7902 WELLINGTON To: C&C DHB BOARD Through: Margot Date: May Subject: Resource Allocation & Cardiovascular Resource Allocation EXECUTIVE SUMMARY In October 2002 the Board asked CPHAC (its Community and Public Health Advisory Committee) to begin a program
ARON FARREL STEIN, Ph.D. 858-523-9215 (Office) 858-523-0280 (Fax) SUMMARY: Over 20 years of pharmaceutical experience with demonstrated ability to lead, build, mentor, develop, and manage in both small and large organizations. Broad areas of management responsibilities include Toxicology, Regulatory and Medical Affairs, and Quality Assurance. Strategic FDA initiatives involved partneri